Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: A study conducted for the Netherlands

被引：16

作者：

Boersma C. ^{[1
,2
]}

Klok R.M. ^{[1
]}

Bos J.M. ^{[1
]}

Naunton M. ^{[1
]}

Van Den Berg P.B. ^{[1
]}

De Jongvan Den Berg L.T.W. ^{[1
]}

Postma M.J. ^{[1
]}

机构：

[1] Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University for Drug Exploration (GUIDE), Groningen

[2] 9713 AV Groningen

来源：

Applied Health Economics and Health Policy | 2005年 / 4卷 / 3期

关键词：

Fluoxetine; Ranitidine; Enalapril; Generic Drug; Price Competition;

D O I：

10.2165/00148365-200504030-00008

中图分类号：

学科分类号：

摘要：

Background: In order to increase price competition, government regulations focus on controlling drug costs. Drug costs after patent expiry are an area of particular interest because the substitution of branded medication with generics represents an opportunity for lowering drug costs. However, drug costs may not decrease after patent expiry, because of a lack of price competition and different national pricing systems. Aim: The aim of this study was to investigate the trends in the use of generics after patent expiry for enalapril, fluoxetine and ranitidine and the subsequent changes, if any, in the costs of these medications. Methods: A drug-utilisation study was performed using data from a large sample of Dutch pharmacies. Both volumes (measured as defined daily doses [DDD] per 1000 population) as well as drug costs (calculated per DDD) prior to and after patent expiry were calculated. Costs per DDD were compared using trend-line analysis. In addition, the relative market shares of the different trade channels (branded, parallel imported and generic) were compared before and after patent expiry. Results: The costs per DDD decreased for all three drugs and, as expected, these costs decrease more rapidly after patent expiry. Significant differences in the trend lines were found for enalapril and fluoxetine. Conclusions: Despite relatively high reimbursement prices for generics in the Netherlands, this example from the Dutch pharmaceutical market demonstrates the benefit of generic substitution for containing pharmaceutical costs, which contrasts with concerns raised by the Dutch government. © 2005 Adis Data Information BV. All rights reserved.

引用

页码：191 / 196

页数：5

共 17 条

[1]

Canton E., Westerhout E., A model for the Dutch pharmaceutical market, Health Econ, 8, pp. 391-402, (1999)

[2]

Werko L., The rapidly increasing cost of medicines threatens the core of healthcare, Scand Cardiovasc J, 38, pp. 130-131, (2004)

[3]

Lopez-Casanovas G., Puig-Junoy J., Review of the literature on reference pricing, Health Policy, 54, pp. 87-123, (2000)

[4]

Ess S.M., Schneeweiss S., Szucs T.D., European healthcare policies for controlling drug expenditure, Pharmacoeconomics, 21, 2, pp. 89-103, (2003)

[5]

Garattini L., Tediosi F., A comparative analysis of generics markets in five European countries, Health Policy, 51, 3, pp. 149-162, (2000)

[6]

Vogel R.J., Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union, Clin Ther, 26, 8, pp. 1327-1340, (2004)

[7]

Mrazek M.F., Comparative approaches to pharmaceutical price regulation in the European Union, Croat Med J, 43, 4, pp. 453-461, (2002)

[8]

Magazzini L., Pammolli F., Riccaboni M., Dynamic competition in pharmaceuticals: Patent expiry, generic penetration, and industry structure, Eur J Health Econ, 5, pp. 175-182, (2004)

[9]

King D.R., Kanavos P., Encouraging the use of generic medicines: Implications for transition economies, Croat Med J, 43, 4, pp. 462-469, (2002)

[10]

Pronk M.H., Bonsel G.J., Van Der Kuy A., The budget control function of the drug reimbursement system, Ned Tijdschr Geneeskd, 146, 37, pp. 1729-1733, (2002)

← 1 2 →